TAK-279

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

PsoriasisUlcerative Colitis

102 competitors in Psoriasis

#DrugCompanyPhaseTrials

1

Daliresp

AstraZeneca

Phase 3

52

Zasocitinib

Takeda

Phase 3

13

D-2570

IInventisBio Co., Ltd

Phase 3

44

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

25

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

16

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

47

HSK44459

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

18

TAK-279

Takeda

Phase 3

39

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

310

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Psoriasis3 trials

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting·Takeda·Phase 3·NCT06550076·1,950 enrolled

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Completed·Takeda·Phase 3·NCT06088043·693 enrolled

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Completed·Takeda·Phase 3·NCT06108544·1,108 enrolled

Adult3 trials

A Study of TAK-279 in Adults With or Without Liver Damage

Completed·Takeda·Phase 1·NCT05976321·27 enrolled

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Completed·Takeda·Phase 1·NCT06258265·120 enrolled

A Study of TAK-279 in Healthy Chinese Adults

Completed·Takeda·Phase 1·NCT06111547·24 enrolled

Interaction2 trials

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed·Takeda·Phase 1·NCT05995249·172 enrolled

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Completed·Takeda·Phase 1·NCT06290050·20 enrolled

Kidney1 trial

A Study of TAK-279 in Adults With or Without Kidney Problems

Completed·Takeda·Phase 1·NCT05992155·24 enrolled

Generalized Pustular Psoriasis1 trial

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Completed·Takeda·Phase 3·NCT06323356·18 enrolled

2 more indications

Crohn's Disease1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting·Takeda·Phase 2·NCT06233461·268 enrolled

Ulcerative Colitis1 trial

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Takeda·Phase 2·NCT06254950·213 enrolled

Details

Drug Info

Related News